Autolus Therapeutics vs Immunocore
AUTL and IMCR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AUTL and IMCR compare
Immunocore is the larger company, worth 4.9 times as much as Autolus Therapeutics ($1.4B against $290M).
Autolus Therapeutics grew revenue faster over the last twelve months (292% versus 21.0% for Immunocore).
Immunocore keeps more of each dollar of sales as profit, with a net margin of −4.2% compared with −239% at Autolus Therapeutics.
Immunocore scores higher on the StockData Score (7 against 5 for Autolus Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AUTL | IMCR |
|---|---|---|
| Size and price | ||
| Market cap | $290M | $1.4B |
| Share price | $1.09 | $27.81 |
| Change, 1 year | −20.4% | −22.6% |
| Change, 5 years | −82.6% | −23.6% |
| Beta (5Y) | 3.47 | 0.19 |
| Employees | 754 | 524 |
| StockData Score | ||
| Total score | 5 | 7 (better) |
| Valuation score | 1 | 1 |
| Growth score | 3 (better) | 2 |
| Performance score | 0 | 3 (better) |
| Health score | 1 | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 2.5× (better) | 3.3× |
| P/B | 3.9× | 3.4× (better) |
| FCF yield | −80.2% | −2.9% (better) |
| Fair value | $1.36 | $32.29 |
| Margin of safety | 19.8% (better) | 13.9% |
| Growth | ||
| Revenue growth (TTM) | 292% (better) | 21.0% |
| Profitability | ||
| Gross margin | 15.7% | 98.9% (better) |
| Operating margin | −211% | −5.2% (better) |
| Net margin | −239% | −4.2% (better) |
| FCF margin | −198% | −9.6% (better) |
| Return on equity | −133% | −4.5% (better) |
| Financial health | ||
| Interest coverage | −5.9× | −1.8× (better) |
| Current ratio | 4.89 (better) | 4.47 |
| Altman Z-score | −4.60 | 1.40 (better) |
| Piotroski F-score | 2 | 3 (better) |
| Dividends and buybacks | ||
| Dividend yield | – | 0.00% |
| Years of dividend growth | – | 0 |
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 49.7% | 102% |
| Held by insiders | 24.6% | 15.5% |
| Insider net buying, 12 months | −$15.7K (better) | −$1.9M |
Go deeper
- AUTL stock overview
- AUTL income statement
- AUTL valuation and score
- IMCR stock overview
- IMCR income statement
- IMCR valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.